尼麦角林长程给药治疗脑梗死和预防其再发的研究

目的:探讨尼麦角林长程给药治疗脑梗死和预防其再发的效果及其机制.方法:120例脑梗死患者随机分为实验组60例,对照组60例,两组常规治疗相同,实验组在常规治疗的基础上给于尼麦角林30mg,早晨服用,治疗半年以上.观察两组1个月的临床疗效和1年内的再发率,并于治疗前和治疗后1年,分别进行血脂和血小板聚集率检查.结果:实验组在治疗1个月的显效率为80%,总有效率98.3%,明显高于对照51.6%和71.6%(均P＜0.01);1a内的再发率为5.83%,明显低于对照组的26.89%.(P＜0.01).与脑梗死再发率有关的血黏度、血脂、纤维蛋白原及血小板聚集率等指标防治组也明显低于对照组(均P＜0.01).结论:尼麦角林长程给药不仅可提高疗效而且可有效预防脑梗死再发.

Study on Treatment and Preventing Re-attack of Cerebral Infartcion in Taking Nicergoline Long Term

Objective:To explore the effect and mechanism of taking nicergoline long tenm for treatment and preventing the attack again of cerebral infartcion. Methods:120 patients with cerebral infarction were divided into 2 groups randomly,preventing group (60 cases) and control group(60 cases) The basic treatment in the two groups are the same . The preventing group was taken niurgline 30 mg once every evering,at least 6 months. To observe the clinical effect in 1 month and the rate of attack again in 1 year. The two groups were measured on blood lipid and platelet aggregation rate before ancl after treatment one year. Results:After treatment one month,the significant effective rate in nicergoline preventing group is 80%,the total effective rate is 98.3%,but the control group is 51.6% and 71.6%(all p<0.01); the rate of attack again in one year is 5.83%,the control group is 26.89%(p<0.01) The blood viscosity,blood lipid,fibrin and the platelet aggregation rate relating to attack again of cerebral infarction are lower significantly than the control group (all p<0.01). Conclusion:Taking nicergoline long term may prevent the attack again of cerebral infarction operatively,the macherism may be relating to decrease blood lipid and anti-platelet aggregation.